CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 207 enrolled
Drug / intervention
Zonisamide +1 moredrug
Likely dose
Zonisamide 8mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00566254
NCT00566254Phase 3Completed

A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures

Eisai Inc.·interventional·Posted Dec 3, 2007·Updated May 13, 2013

In Brief

A Phase 3 clinical trial evaluating Zonisamide and Placebo for Epilepsy; Paediatric Partial Onset Seizures. Completed, enrolled 207 participants across 43 sites in 9 countries.

Detailed Summary

The purpose of this study is to compare the safety and efficacy of zonisamide with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Estonia, France, Hungary, Italy, Latvia, Poland, Spain, Ukraine
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 3, 2007
Enrollment StartDec 1, 2008
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.6 years ago

Interventions

Zonisamidedrug

8mg/kg per day for approximately 24 weeks.

Placebodrug